MeSH tree: C04.557.470.200.025
Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead increase the risk of chronic liver damage and cancer as we age.
Jan 13, 2026
0
21
Large language models (LLM) can generate treatment recommendations for straightforward cases of hepatocellular carcinoma (HCC) that align with clinical guidelines but fall short in more complex cases, according to a new study ...
Jan 13, 2026
0
25
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment.
Jan 7, 2026
0
22
Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short-term illness (acute hepatitis) and a life-threatening infection called chronic hepatitis B.
Jan 5, 2026
0
32
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target tumors. Despite their initial clinical success, many patients eventually experience diminished therapeutic ...
Dec 29, 2025
0
21
One of the biggest risk factors for developing liver cancer is a high-fat diet. A new study from MIT reveals how a fatty diet rewires liver cells and makes them more prone to becoming cancerous.
Dec 22, 2025
0
133
Four of the top medical leaders in Virginia have signed a letter opposing a vote last week by a Centers for Disease Control committee to end the agency's recommendation for universal hepatitis B vaccines for all newborns ...
Dec 18, 2025
0
13
Researchers have developed an AI-based tool that accelerates the detection of kidney cancer. Its effectiveness was validated in a study published in Communications Medicine.
Dec 18, 2025
0
20
Illinois should continue to recommend that nearly all newborns be vaccinated against hepatitis B, a state advisory committee decided Tuesday, in a move that could represent another break with federal vaccine guidance.
Dec 17, 2025
0
11
University of California, San Francisco investigators led WISDOM, a randomized comparison of risk-based breast cancer screening and annual mammography. Rates of stage ≥IIB breast cancers met a noninferiority threshold under ...
